Publication Information

{'id': 'https://openalex.org/W2463309567', 'doi': None, 'title': 'Cost of dose escalation in people with rheumatoid arthritis treated with tumour necrosis factor inhibitors across Europe.', 'display_name': 'Cost of dose escalation in people with rheumatoid arthritis treated with tumour necrosis factor inhibitors across Europe.', 'publication_year': 2016, 'publication_date': '2016-05-19', 'ids': {'openalex': 'https://openalex.org/W2463309567', 'mag': '2463309567', 'pmid': 'https://pubmed.ncbi.nlm.nih.gov/27191345'}, 'language': 'en', 'primary_location': {'is_oa': False, 'landing_page_url': 'https://pubmed.ncbi.nlm.nih.gov/27191345', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S4306525036', 'display_name': 'PubMed', 'issn_l': None, 'issn': None, 'is_oa': False, 'is_in_doaj': False, 'is_core': False, 'host_organization': 'https://openalex.org/I1299303238', 'host_organization_name': 'National Institutes of Health', 'host_organization_lineage': ['https://openalex.org/I1299303238'], 'host_organization_lineage_names': ['National Institutes of Health'], 'type': 'repository'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}, 'type': 'article', 'type_crossref': 'journal-article', 'indexed_in': ['pubmed'], 'open_access': {'is_oa': False, 'oa_status': 'closed', 'oa_url': None, 'any_repository_has_fulltext': False}, 'authorships': [{'author_position': 'first', 'author': {'id': 'https://openalex.org/A5060122823', 'display_name': 'Sarah E. Holden', 'orcid': 'https://orcid.org/0000-0002-4315-5681'}, 'institutions': [], 'countries': ['GB'], 'is_corresponding': False, 'raw_author_name': 'Sarah E Holden', 'raw_affiliation_strings': ['Global Epidemiology, Pharmatelligence, Cardiff, UK.'], 'affiliations': [{'raw_affiliation_string': 'Global Epidemiology, Pharmatelligence, Cardiff, UK.', 'institution_ids': []}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5077893105', 'display_name': 'Craig J. Currie', 'orcid': 'https://orcid.org/0000-0002-6154-818X'}, 'institutions': [{'id': 'https://openalex.org/I72054575', 'display_name': 'Cochrane', 'ror': 'https://ror.org/00dbkrq51', 'country_code': 'GB', 'type': 'nonprofit', 'lineage': ['https://openalex.org/I72054575']}, {'id': 'https://openalex.org/I79510175', 'display_name': 'Cardiff University', 'ror': 'https://ror.org/03kk7td41', 'country_code': 'GB', 'type': 'education', 'lineage': ['https://openalex.org/I79510175']}], 'countries': ['GB'], 'is_corresponding': False, 'raw_author_name': 'Craig J Currie', 'raw_affiliation_strings': ['Global Epidemiology, Pharmatelligence, Cardiff; and The Cochrane Institute of Primary Care and Public Health, School of Medicine, Cardiff University, UK. [email protected].'], 'affiliations': [{'raw_affiliation_string': 'Global Epidemiology, Pharmatelligence, Cardiff; and The Cochrane Institute of Primary Care and Public Health, School of Medicine, Cardiff University, UK. [email protected].', 'institution_ids': ['https://openalex.org/I72054575', 'https://openalex.org/I79510175']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5077211184', 'display_name': 'Martin Lennon', 'orcid': None}, 'institutions': [], 'countries': ['GB'], 'is_corresponding': False, 'raw_author_name': 'Martin Lennon', 'raw_affiliation_strings': ['ELM Medical, Stafford, UK.'], 'affiliations': [{'raw_affiliation_string': 'ELM Medical, Stafford, UK.', 'institution_ids': []}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5016990523', 'display_name': 'Alan Reynolds', 'orcid': 'https://orcid.org/0000-0003-0554-8107'}, 'institutions': [], 'countries': ['GB'], 'is_corresponding': False, 'raw_author_name': 'Alan V Reynolds', 'raw_affiliation_strings': ['Reynolds Clinical Sciences Ltd, Eastleigh, Hants, UK.'], 'affiliations': [{'raw_affiliation_string': 'Reynolds Clinical Sciences Ltd, Eastleigh, Hants, UK.', 'institution_ids': []}]}, {'author_position': 'last', 'author': {'id': 'https://openalex.org/A5075906091', 'display_name': 'Robert J. Moots', 'orcid': 'https://orcid.org/0000-0001-7019-6211'}, 'institutions': [{'id': 'https://openalex.org/I4210089066', 'display_name': 'Aintree University Hospital', 'ror': 'https://ror.org/008j59125', 'country_code': 'GB', 'type': 'healthcare', 'lineage': ['https://openalex.org/I2799272705', 'https://openalex.org/I4210089066']}, {'id': 'https://openalex.org/I146655781', 'display_name': 'University of Liverpool', 'ror': 'https://ror.org/04xs57h96', 'country_code': 'GB', 'type': 'education', 'lineage': ['https://openalex.org/I146655781']}], 'countries': ['GB'], 'is_corresponding': False, 'raw_author_name': 'Robert J Moots', 'raw_affiliation_strings': ['Department of Musculoskeletal Biology, Institute of Ageing and Chronic Diseases, University of Liverpool, Clinical Sciences Centre, University Hospital Aintree, Liverpool, UK.'], 'affiliations': [{'raw_affiliation_string': 'Department of Musculoskeletal Biology, Institute of Ageing and Chronic Diseases, University of Liverpool, Clinical Sciences Centre, University Hospital Aintree, Liverpool, UK.', 'institution_ids': ['https://openalex.org/I4210089066', 'https://openalex.org/I146655781']}]}], 'institution_assertions': [], 'countries_distinct_count': 1, 'institutions_distinct_count': 4, 'corresponding_author_ids': [], 'corresponding_institution_ids': [], 'apc_list': None, 'apc_paid': None, 'fwci': 0.0, 'has_fulltext': False, 'cited_by_count': 1, 'citation_normalized_percentile': {'value': 0.49605, 'is_in_top_1_percent': False, 'is_in_top_10_percent': False}, 'cited_by_percentile_year': {'min': 66, 'max': 73}, 'biblio': {'volume': '34', 'issue': '4', 'first_page': '679', 'last_page': '84'}, 'is_retracted': False, 'is_paratext': False, 'primary_topic': {'id': 'https://openalex.org/T10200', 'display_name': 'Rheumatoid Arthritis Research and Therapies', 'score': 0.9849, 'subfield': {'id': 'https://openalex.org/subfields/2745', 'display_name': 'Rheumatology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, 'topics': [{'id': 'https://openalex.org/T10200', 'display_name': 'Rheumatoid Arthritis Research and Therapies', 'score': 0.9849, 'subfield': {'id': 'https://openalex.org/subfields/2745', 'display_name': 'Rheumatology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T11157', 'display_name': 'Chronic Lymphocytic Leukemia Research', 'score': 0.9712, 'subfield': {'id': 'https://openalex.org/subfields/2716', 'display_name': 'Genetics'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T11725', 'display_name': 'Immunodeficiency and Autoimmune Disorders', 'score': 0.9678, 'subfield': {'id': 'https://openalex.org/subfields/2403', 'display_name': 'Immunology'}, 'field': {'id': 'https://openalex.org/fields/24', 'display_name': 'Immunology and Microbiology'}, 'domain': {'id': 'https://openalex.org/domains/1', 'display_name': 'Life Sciences'}}], 'keywords': [{'id': 'https://openalex.org/keywords/tnf-inhibitor', 'display_name': 'TNF inhibitor', 'score': 0.612701}], 'concepts': [{'id': 'https://openalex.org/C2780132546', 'wikidata': 'https://www.wikidata.org/wiki/Q348260', 'display_name': 'Adalimumab', 'level': 3, 'score': 0.9258987}, {'id': 'https://openalex.org/C2777575956', 'wikidata': 'https://www.wikidata.org/wiki/Q187255', 'display_name': 'Rheumatoid arthritis', 'level': 2, 'score': 0.9109098}, {'id': 'https://openalex.org/C2777138892', 'wikidata': 'https://www.wikidata.org/wiki/Q415264', 'display_name': 'Infliximab', 'level': 3, 'score': 0.9086088}, {'id': 'https://openalex.org/C71924100', 'wikidata': 'https://www.wikidata.org/wiki/Q11190', 'display_name': 'Medicine', 'level': 0, 'score': 0.90674424}, {'id': 'https://openalex.org/C2777226972', 'wikidata': 'https://www.wikidata.org/wiki/Q415343', 'display_name': 'Etanercept', 'level': 3, 'score': 0.87595856}, {'id': 'https://openalex.org/C2779722408', 'wikidata': 'https://www.wikidata.org/wiki/Q1536078', 'display_name': 'TNF inhibitor', 'level': 4, 'score': 0.612701}, {'id': 'https://openalex.org/C17991360', 'wikidata': 'https://www.wikidata.org/wiki/Q21173843', 'display_name': 'Tumor necrosis factor alpha', 'level': 2, 'score': 0.5991677}, {'id': 'https://openalex.org/C126322002', 'wikidata': 'https://www.wikidata.org/wiki/Q11180', 'display_name': 'Internal medicine', 'level': 1, 'score': 0.4910195}, {'id': 'https://openalex.org/C2777077863', 'wikidata': 'https://www.wikidata.org/wiki/Q170990', 'display_name': 'Arthritis', 'level': 2, 'score': 0.47217506}], 'mesh': [{'descriptor_ui': 'D018501', 'descriptor_name': 'Antirheumatic Agents', 'qualifier_ui': 'Q000191', 'qualifier_name': 'economics', 'is_major_topic': True}, {'descriptor_ui': 'D018501', 'descriptor_name': 'Antirheumatic Agents', 'qualifier_ui': 'Q000008', 'qualifier_name': 'administration & dosage', 'is_major_topic': True}, {'descriptor_ui': 'D001172', 'descriptor_name': 'Arthritis, Rheumatoid', 'qualifier_ui': 'Q000191', 'qualifier_name': 'economics', 'is_major_topic': True}, {'descriptor_ui': 'D001172', 'descriptor_name': 'Arthritis, Rheumatoid', 'qualifier_ui': 'Q000188', 'qualifier_name': 'drug therapy', 'is_major_topic': True}, {'descriptor_ui': 'D001688', 'descriptor_name': 'Biological Products', 'qualifier_ui': 'Q000008', 'qualifier_name': 'administration & dosage', 'is_major_topic': True}, {'descriptor_ui': 'D001688', 'descriptor_name': 'Biological Products', 'qualifier_ui': 'Q000191', 'qualifier_name': 'economics', 'is_major_topic': True}, {'descriptor_ui': 'D016527', 'descriptor_name': 'Drug Costs', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': True}, {'descriptor_ui': 'D014409', 'descriptor_name': 'Tumor Necrosis Factor-alpha', 'qualifier_ui': 'Q000037', 'qualifier_name': 'antagonists & inhibitors', 'is_major_topic': True}, {'descriptor_ui': 'D000068879', 'descriptor_name': 'Adalimumab', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D000068879', 'descriptor_name': 'Adalimumab', 'qualifier_ui': 'Q000008', 'qualifier_name': 'administration & dosage', 'is_major_topic': False}, {'descriptor_ui': 'D000068879', 'descriptor_name': 'Adalimumab', 'qualifier_ui': 'Q000191', 'qualifier_name': 'economics', 'is_major_topic': False}, {'descriptor_ui': 'D018501', 'descriptor_name': 'Antirheumatic Agents', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D001172', 'descriptor_name': 'Arthritis, Rheumatoid', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D001172', 'descriptor_name': 'Arthritis, Rheumatoid', 'qualifier_ui': 'Q000276', 'qualifier_name': 'immunology', 'is_major_topic': False}, {'descriptor_ui': 'D001172', 'descriptor_name': 'Arthritis, Rheumatoid', 'qualifier_ui': 'Q000175', 'qualifier_name': 'diagnosis', 'is_major_topic': False}, {'descriptor_ui': 'D001688', 'descriptor_name': 'Biological Products', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D054796', 'descriptor_name': 'Drug Dosage Calculations', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D000068800', 'descriptor_name': 'Etanercept', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D000068800', 'descriptor_name': 'Etanercept', 'qualifier_ui': 'Q000191', 'qualifier_name': 'economics', 'is_major_topic': False}, {'descriptor_ui': 'D000068800', 'descriptor_name': 'Etanercept', 'qualifier_ui': 'Q000008', 'qualifier_name': 'administration & dosage', 'is_major_topic': False}, {'descriptor_ui': 'D005060', 'descriptor_name': 'Europe', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D006801', 'descriptor_name': 'Humans', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D000069285', 'descriptor_name': 'Infliximab', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D000069285', 'descriptor_name': 'Infliximab', 'qualifier_ui': 'Q000191', 'qualifier_name': 'economics', 'is_major_topic': False}, {'descriptor_ui': 'D000069285', 'descriptor_name': 'Infliximab', 'qualifier_ui': 'Q000008', 'qualifier_name': 'administration & dosage', 'is_major_topic': False}, {'descriptor_ui': 'D018803', 'descriptor_name': 'Models, Economic', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D013997', 'descriptor_name': 'Time Factors', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D016896', 'descriptor_name': 'Treatment Outcome', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D014409', 'descriptor_name': 'Tumor Necrosis Factor-alpha', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D014409', 'descriptor_name': 'Tumor Necrosis Factor-alpha', 'qualifier_ui': 'Q000276', 'qualifier_name': 'immunology', 'is_major_topic': False}], 'locations_count': 1, 'locations': [{'is_oa': False, 'landing_page_url': 'https://pubmed.ncbi.nlm.nih.gov/27191345', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S4306525036', 'display_name': 'PubMed', 'issn_l': None, 'issn': None, 'is_oa': False, 'is_in_doaj': False, 'is_core': False, 'host_organization': 'https://openalex.org/I1299303238', 'host_organization_name': 'National Institutes of Health', 'host_organization_lineage': ['https://openalex.org/I1299303238'], 'host_organization_lineage_names': ['National Institutes of Health'], 'type': 'repository'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}], 'best_oa_location': None, 'sustainable_development_goals': [{'score': 0.42, 'id': 'https://metadata.un.org/sdg/17', 'display_name': 'Partnerships for the goals'}], 'grants': [], 'datasets': [], 'versions': [], 'referenced_works_count': 0, 'referenced_works': [], 'related_works': ['https://openalex.org/W2910586724', 'https://openalex.org/W2463309567', 'https://openalex.org/W2345141018', 'https://openalex.org/W2341567294', 'https://openalex.org/W2141436693', 'https://openalex.org/W2064215099', 'https://openalex.org/W2038285281', 'https://openalex.org/W2015993259', 'https://openalex.org/W1981274829', 'https://openalex.org/W1973470095'], 'abstract_inverted_index': {'The': [0, 66, 154], 'aim': [1], 'of': [2, 11, 29, 35, 68, 101, 108, 115, 120, 127, 148, 157, 177, 219], 'this': [3], 'study': [4], 'was': [5, 52, 143, 162, 204], 'to': [6, 139], 'calculate': [7], 'the': [8, 39, 60, 78, 106, 113, 118, 125, 133, 146, 166, 175, 220], 'marginal': [9, 155], 'cost': [10, 46, 107, 119, 135, 156, 169], 'dose': [12, 34, 147, 160, 187], 'escalation': [13, 161, 188, 218], 'in': [14, 43, 168, 181, 189, 227, 234, 237], 'people': [15, 30, 69, 190, 228], 'with': [16, 20, 48, 70, 74, 186, 191, 229], 'rheumatoid': [17, 71, 192, 230], 'arthritis': [18, 72, 193, 231], 'treated': [19, 73], 'tumour': [21], 'necrosis': [22], 'factor': [23], '(TNF)': [24], 'inhibitors': [25, 76, 222], 'across': [26, 194, 241], 'Europe.The': [27], 'proportion': [28], 'who': [31], 'escalate': [32], 'their': [33], 'TNF': [36, 44, 75, 103, 149, 158, 182, 221, 238], 'inhibitor': [37, 45, 104, 150, 159, 183, 239], 'and': [38, 77, 172, 202, 213, 225], 'average': [40], 'percentage': [41], 'increase': [42, 180, 236], 'associated': [47, 185], 'escalators': [49, 116, 171], 'versus': [50], 'non-escalators': [51, 173], 'calculated': [53, 144], 'from': [54, 89], 'previously': [55], 'published': [56], 'estimates,': [57], 'weighted': [58], 'by': [59, 112, 124, 152, 164, 174], 'sample': [61], 'size': [62], 'for': [63, 85, 207, 211, 216], 'each': [64], 'study.': [65], 'number': [67, 114, 126, 176], 'corresponding': [79], 'total': [80, 99, 141], 'drug': [81, 134], 'sales': [82, 100, 142], 'were': [83], 'obtained': [84], 'five': [86, 195, 242], 'European': [87, 196, 243], 'countries': [88, 197], 'Decision': [90], "Resources'": [91], 'Pharmacor': [92], 'Market': [93], 'Forecast.': [94], 'Method': [95, 129], '1': [96], 'assumed': [97, 131], 'that': [98, 132], 'a': [102, 121], 'represented': [105], 'an': [109, 235], 'escalator': [110], 'multiplied': [111, 123], 'plus': [117], 'non-escalator': [122], 'non-escalators.': [128, 153], '2': [130], 'per': [136], 'day': [137], 'used': [138, 151], 'forecast': [140], 'using': [145], 'estimated': [163, 179], 'multiplying': [165], 'difference': [167], 'between': [170], 'escalators.The': [178], 'costs': [184, 240], '(Germany,': [198], 'France,': [199], 'UK,': [200], 'Spain': [201], 'Italy)': [203], '€51.5-54.4': [205], 'million': [206, 210, 215], 'adalimumab,': [208, 223], '€44.8-52.8': [209], 'infliximab': [212, 226], '€5.8-5.9': [214], 'etanercept.Dose': [217], 'etanercept': [224], 'has': [232], 'resulted': [233], 'countries.': [244]}, 'cited_by_api_url': 'https://api.openalex.org/works?filter=cites:W2463309567', 'counts_by_year': [{'year': 2021, 'cited_by_count': 1}], 'updated_date': '2024-12-17T19:29:34.206311', 'created_date': '2016-07-22'}